Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases. Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for patients with inflammatory diseases. Ingelheim, Germany, and
(Financial Post, 2025-10-30T06:44:06Z)